Open access · CC-BY
via OpenAlex
Improved Physical Performance Parameters in Patients Taking Nicotinamide Mononucleotide (NMN): A Systematic Review of Randomized Control Trials
Jimmy Wen, Burhaan Syed, Solomon Kim, Mouhamad Shehabat, Ubaid Ansari, Daniel Razick, Muzammil Akhtar, David Pai
Cureus · 2024 · ▲ 6 citations
Abstract
Nicotinamide adenine dinucleotide (NAD+) is essential in the proper function of many essential cellular processes in the human body. The purpose of this review is to investigate the effect of nicotinamide mononucleotide (NMN), a NAD+ precursor, on physical performance and evaluate the safety profile of supplementation. A systematic review search criteria following the guidelines from the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) was performed in four databases for randomized controlled trials on NMN supplementation. Study variables included title, author, publication date, study year, number of patients, dosage, mean age, mean follow-up time, pre- and post-intervention reported outcomes, and rates of complications. Ten studies, including 437 patients, with a mean age of 58.0 years (35.1 to 81.1 years) and a mean follow-up time of 9.6 weeks (4 to 12 weeks) were included in this study. NMN dosages ranged from 150 to 1200 mg/day. Mean pre-intervention grip strength (two studies) and skeletal mass index (two studies) were 29.9 kilograms (kg) (range: 21.4-40.1 kg) and 7.4 kg/m2 (range: 6.9-7.65 kg/m2), respectively. Mean post-intervention grip strength and skeletal mass index were 30.5 kg (range: 21.7-41.9 kg) and 7.4 kg/m2 (6.8-7.64 kg/m2), respectively. There were no serious adverse effects observed. Moreover, of the reported side effects, they were determined to be independent of NMN supplementation. Therefore, patients taking NMN supplementation demonstrated non-significantly improved physical performance parameters. NMN is well tolerated with no serious adverse effects observed.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.7759/cureus.65961
- Canonical
- link ↗
- Fetched
- 2026-10-31 MST
Cite this
APA
Wen, J., Syed, B., Kim, S., Shehabat, M., Ansari, U., Razick, D., Akhtar, M., & Pai, D. (2024). Improved Physical Performance Parameters in Patients Taking Nicotinamide Mononucleotide (NMN): A Systematic Review of Randomized Control Trials. <em>Cureus</em>. https://doi.org/10.7759/cureus.65961
Vancouver
Wen J, Syed B, Kim S, Shehabat M, Ansari U, Razick D, et al. Improved Physical Performance Parameters in Patients Taking Nicotinamide Mononucleotide (NMN): A Systematic Review of Randomized Control Trials. Cureus. 2024. doi:10.7759/cureus.65961.
BibTeX
@article{jimmy2024Improv,
title = {Improved Physical Performance Parameters in Patients Taking Nicotinamide Mononucleotide (NMN): A Systematic Review of Randomized Control Trials},
author = {Jimmy Wen and Burhaan Syed and Solomon Kim and Mouhamad Shehabat and Ubaid Ansari and Daniel Razick and Muzammil Akhtar and David Pai},
journal = {Cureus},
year = {2024},
doi = {10.7759/cureus.65961},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Journal of Cachexia Sarcopenia and Muscle 2025
Open access · CC-BY
The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta‐Analysis
Advances in Nutrition 2023
Open access · CC-BY
The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update
Journal of Nutrition 2021
Open access · OA
NAD+-Precursor Supplementation With L-Tryptophan, Nicotinic Acid, and Nicotinamide Does Not Affect Mitochondrial Function or Skeletal Muscle Function in Physically Compromised Older Adults
Scientific reports 2026
Citation only
Systematic review and meta-analysis of the effects of exercise in older adults with sarcopenia.
Nutrients 2021
Open access · CC-BY
Potential Role of Probiotics for Inflammaging: A Narrative Review
Advances in nutrition (Bethesda, Md.) 2026
Open access · OA